Schwartz H I
Department of Psychiatry, Hartford Hospital, Connecticut 06115.
Hosp Community Psychiatry. 1992 Apr;43(4):382-5. doi: 10.1176/ps.43.4.382.
In 1989 New York became the first state to add benzodiazepines to the list of controlled substances requiring a triplicate prescription, allowing the state to track prescribing patterns and target providers, pharmacies, and patients for investigation when misuse is suspected. Studies by the state reporting that regulation has significantly reduced inappropriate prescribing and illicit diversion of benzodiazepines without affecting legitimate prescribing practices are being challenged by other studies showing that patients with legitimate needs for benzodiazepines are being denied them, often after abrupt discontinuation. Several reports indicate a significant increase in the prescribing of benzodiazepine substitutes that are less safe and effective, along with increased overdoses of some substitute drugs. Changes in physicians' legitimate prescribing practices may reflect their fears of the damage to career and peace of mind that follows investigations by regulatory agencies.
1989年，纽约成为首个将苯二氮䓬类药物列入需要三联处方的管制药品清单的州，这使得该州能够追踪处方模式，并在怀疑存在滥用情况时，将开处方者、药店和患者作为调查对象。该州的研究报告称，这项管制措施显著减少了苯二氮䓬类药物的不当处方和非法转移，且未影响合法的处方行为，但其他研究对这一结论提出了质疑，这些研究表明，有合法需求的患者往往在突然停药后被拒绝开具苯二氮䓬类药物。几份报告显示，安全性和有效性较低的苯二氮䓬类替代药物的处方量显著增加，同时一些替代药物的过量服用情况也有所增加。医生合法处方行为的变化可能反映出他们担心监管机构的调查会对其职业和心境造成损害。
